News and Events

Launch of New Product-Pegneugen (Telpegfilgrastim Injection)

Xiamen, China, July 1, 2023/--Xiamen Amoytop Biotech Co., Ltd. (referred to as Amoytop Biotech hereinafter) today announced that Pegneugen® (Telpegfilgrastim Injection) has been approved by National Medical Products Administration (NMPA) and is available for marketing.

Amoytop's Quality Center awarded CNAS certificate

Recently, Amoytop's Quality Center was awarded the certificate issued by China National Accreditation Service for Conformity Assessment (CNAS) (Certificate number: CNAS L4479).

Hepatitis B new drug from China shines in the United States, "Chinese wisdom" brings new hope for hepatitis B cure.

GMP approval of Amoytop Biotech by State Food and Drug Administration (No. 164, 2016)